27,862 results match your criteria Atopic Dermatitis


A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services.

J Allergy Clin Immunol Pract 2020 May 22. Epub 2020 May 22.

Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. Electronic address:

In early 2020, the first US and Canadian cases of the novel SARS-CoV-2 infection were detected. In the ensuing months, there has been rapid spread of the infection. In March 2020, in response to the virus, state/provincial and local governments instituted shelter-in-place orders, and non-essential ambulatory care was significantly curtailed, including allergy/immunology services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2020.05.012DOI Listing

Patient-oriented Eczema Measure score: a Useful Tool for Web-Based Surveys in Patients with Atopic Dermatitis.

Acta Derm Venereol 2020 May 25. Epub 2020 May 25.

Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 812-8582 Fukuoka, Japan. E-mail:

The Patient-Oriented Eczema Measure (POEM, 0-28 points) is a self-assessed, repeatable measurement tool for measuring atopic dermatitis (AD) severity. How-ever, whether POEM score is influenced by allergic comorbidities and whether POEM's severity banding is applicable in web-based surveys for AD remain unclear. A web-based questionnaire survey was conducted in 329 patients with AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3530DOI Listing

Psychological Consequences of the Most Common Dermatoses: Data from the Objectifs Peau Study.

Acta Derm Venereol 2020 May 25. Epub 2020 May 25.

Department of Dermatology and Venereology, University Hospital of Brest, FR-29200 Brest, France. E-mail:

The prevalence of psychological disorders in patients with common skin diseases was assessed in a large representative sample of the French adult population. General health, as measured by the EQ5D score, was significantly lower if patients reported having rosacea, atopic dermatitis, urticaria, fungal infections, psoriasis or acne. The proportions of participants reporting being extremely anxious or depressed were higher in those who reported having rosacea, atopic dermatitis or contact dermatitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3531DOI Listing

Face Mask-induced Itch: A Self-questionnaire Study of 2,315 Responders During the COVID-19 Pandemic.

Acta Derm Venereol 2020 May 25. Epub 2020 May 25.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, ul. Chalubinskiego 1, PL-50-368 Wrocław, Poland. E-mail:

Little is known about itch related to the use of face masks. This internet survey study investigated the prevalence, intensity and clinical characteristics of itch related to the use of face masks by the general public during the COVID-19 pandemic. A total of 2,315 replies were received, of which 2,307 were included in the final analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3536DOI Listing

Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients with Long-Term Dupilumab Use.

J Cutan Med Surg 2020 May 25:1203475420929920. Epub 2020 May 25.

7938 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420929920DOI Listing

[The annual cost of medical care for patients with moderate to severe atopic dermatitis in Mexico. A multicenter study].

Rev Alerg Mex 2020 Jan-Mar;67(1):9-18

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Hospital Regional Lic. Adolfo López Mateos, Servicio de Dermatología, Ciudad de México, México.

Background: In Mexico, the economic burden of medical care for patients with atopic dermatitis is unknown.

Objective: To determine the annual direct medical costs of the treatment for patients with moderate to severe atopic dermatitis who receive medical attention at "Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado" (Institute for Social Security and Social Services for State Workers, better known as ISSSTE), as well as the main variables associated with it.

Methods: A multicenter, retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29262/ram.v67i1.700DOI Listing

COVID-19, quarantine, and atopic dermatitis.

Med Hypotheses 2020 May 19;143:109852. Epub 2020 May 19.

Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mehy.2020.109852DOI Listing

A Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes.

J Am Acad Dermatol 2020 May 21. Epub 2020 May 21.

Dermavant Sciences, Inc., Durham, NC, USA.

Background: Tapinarof cream is a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for treatment of psoriasis and atopic dermatitis.

Methods: In a phase IIb, double-blind, vehicle-controlled study, adults with plaque psoriasis were randomized to tapinarof cream 0.5% or 1% once (QD) or twice daily (BID) or vehicle QD or BID for 12 weeks with 4-week follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.181DOI Listing

Illness perceptions and quality of life in families with child with atopic dermatitis.

Allergol Immunopathol (Madr) 2020 May 20. Epub 2020 May 20.

Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

Objective: To assess the Quality of Life (QoL) of children with Atopic Dermatitis (AD) and their families and the impact of the mothers' illness perceptions on the family QoL.

Materials And Methods: Seventy-five children with AD (54 infants and 21 children) and their mothers participated in the study. The following questionnaires were administrated: 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aller.2020.03.003DOI Listing

Origins of allergic disease: Maternal and early childhood factors.

Ann Allergy Asthma Immunol 2020 May 20. Epub 2020 May 20.

Department of Pediatrics, National Jewish Health, Denver, CO 80206.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2020.05.013DOI Listing

The Role of Genetics, the Environment, and Epigenetics in Atopic Dermatitis.

Adv Exp Med Biol 2020 ;1253:107-140

Department of Dermatology, Peking University People's Hospital, Beijing, China.

Atopic Dermatitis (AD) is a common inflammatory disease with a genetic background. The prevalence of AD has been increasing in many countries. AD patients often have manifestations of pruritus, generalized skin dryness, and eczematous lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-981-15-3449-2_4DOI Listing
January 2020

Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study.

J Cutan Med Surg 2020 May 22:1203475420928907. Epub 2020 May 22.

7938 12365 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.

Background: Systemic therapy for atopic dermatitis (AD) has been challenging with limited safe and efficacious long-term treatment options. In 2017, dupilumab was approved in the United States, Europe, and Canada as the first targeted therapy for patients with moderate-to-severe AD. Despite promising efficacy and safety results in clinical trials, our understanding of dupilumab in clinical practice remains limited with few studies outside clinical trials in literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420928907DOI Listing

The clinical significance of fungi in atopic dermatitis.

Int J Dermatol 2020 May 22. Epub 2020 May 22.

Translational Research in Inflammation and Immunology Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases and is caused by multiple factors including genetic factors, skin barrier defects, host immune responses, allergen sensitivity, environmental effects, and infections. Commonly, bacterial and viral infections are present in the eczematous lesions of AD patients and clearly aggravate the symptoms. However, studies of fungal infections in AD are limited in spite of the fact that there are reports showing that Malassezia, Candida, and some dermatophytes can affect the symptoms of AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14941DOI Listing

Infection, antibiotic exposure and development of atopic dermatitis: A nationwide case-control study.

J Dermatol 2020 May 22. Epub 2020 May 22.

Laboratory of Cutaneous Aging and Hair Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.

Previous studies suggest an association between atopic dermatitis (AD) and exposure to microorganisms and antibiotics. However, these studies have limitations, and the sole influence on the development of AD was elusive. We performed a nationwide population-based case-control study in a Korean population to investigate the association between AD and early-life infection or antibiotic exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15387DOI Listing

Fabric Selection in Atopic Dermatitis: An Evidence-Based Review.

Am J Clin Dermatol 2020 May 21. Epub 2020 May 21.

Eczema and Skin Barrier Research Program, Dermatology Division, Department of Medicine, University of Arizona, 7165 N Pima Canyon Drive, Tucson, AZ, 85718, USA.

Background: Clothing fabrics interact closely with the skin to shape our cutaneous microenvironment. Cotton and silk have been traditionally recommended for patients with atopic dermatitis because of reported patient comfort. New synthetic fabrics combine anti-microbial, anti-inflammatory, moisture-wicking, and soothing properties that may augment conventional management strategies in atopic patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00516-0DOI Listing

Caffeoyl-Pro-His amide relieve DNCB-Induced Atopic Dermatitis-Like phenotypes in BALB/c mice.

Sci Rep 2020 May 21;10(1):8417. Epub 2020 May 21.

Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.

The main factors involved in the pathogenesis of atopic dermatitis (AD) are skin barrier abnormality, allergy/immunology, and pruritus. Considering how oxidative stress influences these factors, antioxidant agents may be effective candidates in the treatment of AD. To evaluate the effect of Caffeoyl-Pro-His amide (CA-PH), an antioxidant agent, on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like phenotypes in BALB/c mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65502-2DOI Listing

The role of thymus and activation-regulated chemokine as a marker of severity of atopic dermatitis.

J Am Acad Dermatol 2020 May 18. Epub 2020 May 18.

Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.052DOI Listing

POLYGENIC RISK SCORE FOR ATOPIC DERMATITIS IN THE CANADIAN POPULATION.

J Allergy Clin Immunol 2020 May 18. Epub 2020 May 18.

Département des sciences fondamentales, Université du Québec à Chicoutimi, Saguenay, Quebec, Canada; Centre intersectoriel en santé durable, Université du Québec à Chicoutimi, Saguenay, Quebec, Canada; Department of Pediatrics, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Quebec, Canada. Electronic address:

Capsule Summary: To benefit from early and simple interventions that were prove efficient to prevent the atopic march, this study proposes a polygenic risk score having an area under the curve of 88% to identify high-risk children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.04.057DOI Listing

NK cells as a possible new player in atopic dermatitis.

J Allergy Clin Immunol 2020 May 18. Epub 2020 May 18.

Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.04.052DOI Listing

Ocular surface disease associated with dupilumab treatment for atopic diseases.

Ocul Surf 2020 May 18. Epub 2020 May 18.

The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Dupilumab is the first US FDA approved biologic for treatment of atopic dermatitis. It is a human monoclonal antibody which blocks the shared receptor component, the interleukin (IL)-4α subunit, of IL-4 and IL-13 signaling pathways. Occurrence of "conjunctivitis", mostly in atopic dermatitis trials, has been the main side effect reported thus far. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtos.2020.05.008DOI Listing

Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP).

G Ital Dermatol Venereol 2020 May 21. Epub 2020 May 21.

Dermatology Unit, Catholic University of Rome, and Fondazione Policlinico A. Gemelli - IRCCS, Rome, Italy.

Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.20.06654-7DOI Listing

Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis.

Int J Mol Sci 2020 May 19;21(10). Epub 2020 May 19.

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31-98166 Messina, Italy.

Atopic dermatitis (AD) is a chronic inflammatory disease of the skin, characterized by dryness and more or less severe itching. The etiology of AD is complex and has not been fully clarified, involving genetic susceptibility, immunological abnormalities, epidermal barrier dysfunction, and environmental factors. Xyloglucan (XG) and pea protein (PP) are two compounds of natural origin characterized by the ability to create a physical barrier that protects mucosae membranes, reducing inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21103596DOI Listing

Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation.

Biomolecules 2020 May 19;10(5). Epub 2020 May 19.

College of Pharmacy, Keimyung University, Daegu 42601, Korea.

While liquiritigenin, isolated from , is known to possess anti-inflammatory activities, it still remains to be known whether liquiritigenin has a suppressive effect on T cell activation and T cell-mediated disease. Here, we used Jurkat T cells to explore an underlying mechanism of pre-treatment with liquiritigenin in activated T cell in vitro and used atopic dermatitis (AD) in vivo to confirm it. We found liquiritigenin blocks IL-2 and CD69 expression from activated T cells by PMA/A23187 or anti-CD3/CD28 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom10050786DOI Listing

A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.

J Dermatolog Treat 2020 May 21:1-9. Epub 2020 May 21.

Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.

The long-term efficacy and safety of dupilumab has been demonstrated in clinical trials and only in few real-world studies. We conducted an extension analysis from a previous 16-week study on 109 adult patients affected by moderate-to-severe atopic dermatitis treated with dupilumab. Eczema-Area-and-Severity-Index (EASI), itch numerical-rating-score (itch-NRS), Dermatology-Life-Quality-Index (DLQI) scores, drug survival rate and occurrence of adverse events after 24 and 48 weeks of dupilumab treatment were retrospectively collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1773379DOI Listing

Cesarean Delivery and the Risk of Atopic Dermatitis in Children.

Clin Exp Allergy 2020 May 20. Epub 2020 May 20.

School of Community Health Sciences, University of Nevada, Reno, NV, USA.

Background: Cesarean delivery (C-section) may disrupt maternal-infant microbial transfer and alter immune system development and subsequent risk for atopic dermatitis.

Objective: Investigate the association between C-section and atopic dermatitis by age four and examine potential sources of bias in the relationship in a large cohort study.

Methods: Maternal and child information was collected through Kaiser Permanente Northern California's (KPNC) integrated healthcare system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cea.13668DOI Listing

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis.

Dermatol Ther (Heidelb) 2020 May 20. Epub 2020 May 20.

Global Biometrics and Data Management (Statistics), Pfizer Inc., Groton, USA.

Introduction: There is a need to compare efficacy and safety profiles of crisaborole ointment, 2%, versus other topical treatments across randomized clinical trials (RCTs). We performed this review/network meta-analysis to evaluate the comparative efficacy and safety of crisaborole versus other topical pharmacologic therapies for mild-to-moderate atopic dermatitis (AD) among patients aged ≥ 2 years.

Methods: Searches were conducted in MEDLINE, Embase, the Cochrane Collection Central Register of Clinical Trials, and the Database of Abstracts of Reviews of Effects using Ovid to identify English language articles reporting RCTs of topical anti-inflammatory agents in patients aged ≥ 2 years with mild-to-moderate AD published between inception and 10 March 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-020-00389-5DOI Listing

Authors:

Arerugi 2020 ;69(3):218-219

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.69.218DOI Listing
January 2020

[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].

Arerugi 2020 ;69(3):213-217

Department of Pediatrics, National Hospital Organization Fukuoka National Hospital.

Background: Prurigo nodularis is a chronic disease characterized by a hard dome-like or wart-like nodule which is solitary and does not fuse. Prurigo nodularis presents as one of the symptoms of atopic Dermatitis (AD).

Cases: We present three cases of AD children with intractable prurigo nodularis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.69.213DOI Listing
January 2020

[USEFULNESS OF RUPATADINE FOR PRURITUS OF PATIENTS WITH ATOPIC DERMATITIS].

Arerugi 2020 ;69(3):174-183

Clinical Development & Regulatory Strategy Center, Teikoku Seiyaku CO LTD.

Background: Histamine H1 receptor antagonists (antihistamines) are recommended as adjunctive therapy for atopic dermatitis (AD). However, their long-term usefulness and the effect of updosing have not been clarified.

Purpose: To analyzed the long-term usefulness and the effect of updosing of rupatadine, a second generation antihistamine, for patients with AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.69.174DOI Listing
January 2020

Assessment of a causal relationship between body mass index and atopic dermatitis.

J Allergy Clin Immunol 2020 May 17. Epub 2020 May 17.

Skin Research Group, School of Medicine, University of Dundee, Dundee, UK; Department of Dermatology, Ninewells Hospital and Medical School, Dundee, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.04.050DOI Listing

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.

J Clin Pharmacol 2020 May 20. Epub 2020 May 20.

Pfizer Inc, Groton, Connecticut, USA.

Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Results from 2 randomized, double-blind, vehicle-controlled phase 3 studies showed that twice-daily crisaborole in children and adults with mild to moderate atopic dermatitis was efficacious and well tolerated. Initial pharmacokinetics (PK) studies of crisaborole indicated absorption with measurable systemic levels of crisaborole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1624DOI Listing

Patients' preferences of leave-on emollients- a survey on patients with atopic dermatitis.

J Dermatolog Treat 2020 May 20:1-13. Epub 2020 May 20.

Department of Pediatric Pulmonology and Allergy, The Medical University of Warsaw, Żwirki i Wigury 63A, PL-02-091 Warsaw, Poland.

Atopic dermatitis is a chronic disease affecting up to 20% of children. The growing concern relating to the skin barrier dysfunction resulted in development of dermo-cosmetics market. The selection of best emollient is usually based on "trial and error". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1772452DOI Listing

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.

Proc Natl Acad Sci U S A 2020 May 19. Epub 2020 May 19.

Genentech, South San Francisco, CA 94080;

PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolerance. Consistent with this role, PD-1 checkpoint inhibitors have been associated with immune-related adverse events (irAEs), immune toxicities thought to be autoimmune in origin. Analyses of dermatological irAEs have identified an association with improved overall survival (OS) following anti-PD-(L)1 therapy, but the factors that contribute to this relationship are poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1922867117DOI Listing

nasal isolates may have the same genetic profile in atopic dermatitis paediatric patients and their close contacts.

J Med Microbiol 2020 May 20. Epub 2020 May 20.

Laboratório de Infecção Hospitalar, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Atopic dermatitis (AD) is a chronic skin disease that affects up to 20 % of the paediatric population worldwide. colonizes anterior nares and can be transmitted in the home environment, aggravating AD. This study aimed to detect from nares of AD patients and their family contacts, as well as to evaluate the antimicrobial resistance, virulence and clonality of these isolates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1099/jmm.0.001197DOI Listing

Association of atopic dermatitis severity with cognitive function in adults.

J Am Acad Dermatol 2020 May 16. Epub 2020 May 16.

Departments of Medical Social Sciences, Preventive Medicine, Neurology, and Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Background: Atopic dermatitis (AD) is associated with itch, pain, and sleep disturbance, all of which may contribute toward cognitive dysfunction.

Objective: To determine the relationship of AD severity and cognitive function in adults.

Methods: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n=386). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.041DOI Listing

Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis.

J Allergy Clin Immunol 2020 May 16. Epub 2020 May 16.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York; Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York; The Laboratory for Investigative Dermatology, The Rockefeller University, New York. Electronic address:

Capsule Summary: In a clinical trial of moderate-to-severe atopic dermatitis/AD patients treated with anti IL-17mAb/secukinumab, no significant clinical or molecular improvements were seen, even among disease subtypes with high Th-17-skewing (intrinsic/Asian AD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.04.055DOI Listing

Conjunctivitis in patients with atopic dermatitis treated with dupilumab.

Drugs Context 2020 4;9. Epub 2020 May 4.

Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL-13 are key cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor a subunit that blocks both IL-4 and IL-13 signaling and has shown significant efficacy in patients with moderate-to-severe AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7573/dic.2020-2-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216785PMC

Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis.

Allergy 2020 Apr 23. Epub 2020 Apr 23.

Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

Background: Dupilumab is an anti-IL-4Rα antibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD.

Methods: This multicentric, prospective, observational, real-life study included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/all.14338DOI Listing

Pain in Atopic Dermatitis: An Online Population-based Survey.

Acta Derm Venereol 2020 May 19. Epub 2020 May 19.

Department of Dermatology, University Hospital of Brest, FR-29200 Brest, France.

Pruritus in atopic dermatitis has been studied extensively; however, evaluation of skin pain has been very limited. The aim of this study was to evaluate the presence, frequency and characteristics of skin pain in patients with atopic dermatitis. A survey was conducted of a representative sample of 5,000 18-80-year-old individuals selected from the French population according to sex, age, geographical area and socioprofessional status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3521DOI Listing

Corrigendum to 'Korean red ginseng water extract alleviates atopic dermatitis-like inflammatory responses by negative regulation of mitogen-activated protein kinase signaling pathway in vivo'.

Biomed Pharmacother 2020 May 16:110197. Epub 2020 May 16.

College of Pharmacy, Dankook University, Dandae-ro 119, Dongnam, Cheonan, Chungnam, 31116, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2020.110197DOI Listing

IL-15 Expression Pattern in Atopic Dermatitis.

Int Arch Allergy Immunol 2020 May 18:1-5. Epub 2020 May 18.

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland,

Background: An increased expression of interleukin (IL)-15, a cytokine with a key role in stimulating innate and adaptive immune cells, such as dendritic cells (DC), natural killer cells, and T cells, has been observed in infectious and inflammatory diseases, including autoimmune diseases as well as cancer. Atopic dermatitis (AD) is a common inflammatory skin disease characterized by a type 2 immune response.

Objective: To explore the expression of IL-15 and its pattern in AD skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508515DOI Listing

Safety of dupilumab in atopic patients during COVID-19 outbreak.

J Dermatolog Treat 2020 May 18:1-5. Epub 2020 May 18.

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1771257DOI Listing

Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature.

J Korean Med Sci 2020 May 18;35(19):e122. Epub 2020 May 18.

Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Chaga mushrooms are widely used in folk remedies and in alternative medicine. Contrary to many beneficial effects, its adverse effect is rarely reported. We here report a case of end-stage renal disease after long-term taking Chaga mushroom. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3346/jkms.2020.35.e122DOI Listing

A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis.

Acta Derm Venereol 2020 May 15. Epub 2020 May 15.

Department of Dermatology, College of Medicine, Chosun University, 61453 Gwangju, Korea.

Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease that is characterized by complex immune dysregulation and skin barrier dysfunction with a wide variety of clinical phenotypes. Until recently, conventional therapeutic modalities for AD remained rather non-specific despite AD's complex etiology. Failing to take into account the underlying inflammatory pathways led to treatments with inadequate efficacy or unacceptable long-term toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3515DOI Listing

Prevention of Atopic Dermatitis.

Acta Derm Venereol 2020 May 15. Epub 2020 May 15.

Centre of Evidence-Based Dermatology, Queen's Medical Centre, University of Nottingham, NG7 2UH Nottingham, United Kingdom. E-mail:

Despite advances in atopic dermatitis (AD) treatments, research into AD prevention has been slow. Systematic reviews of prevention strategies promoting exclusive and prolonged breastfeeding, or interventions that reduce ingested or airborne allergens during pregnancy and after birth have generally not shown convincing benefit. Maternal/infant supplements such as Vitamin D have also not shown any benefit with the possible exception of omega-3 fatty acids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3516DOI Listing

Skin Microbiome in Atopic Dermatitis.

Acta Derm Venereol 2020 May 15. Epub 2020 May 15.

Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.

Atopic dermatitis is a common inflammatory skin disease with a complex pathogenesis that includes imbalanced immune system signalling, impaired skin barrier and enhanced Staphylococcus aureus skin colonization. The skin bacterial communities are characterized by increasing abundance of S. aureus, leading to reduced diversity compared with the bacterial communities on healthy skin, and increasing disease severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3514DOI Listing

When life is an itch: What harms, helps and heals from the patients' perspective? Differences and similarities among skin diseases.

Dermatol Ther 2020 May 17:e13606. Epub 2020 May 17.

Department of Dermatology, University Hospital Basel, Switzerland.

Itch is the commonest skin-related symptom, associated with a high psychosocial and economic burden. While the main focus of itch research lies on a few chronic skin diseases, only little is known about the perception of itch, itch-aggravating/-relieving factors and treatment preferences in patients with acute and chronic itch of various etiology. In this cross-sectional study we assessed these aspects in 126 patients (mean age 61. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13606DOI Listing

Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice.

Pharmacol Res 2020 May 14;158:104878. Epub 2020 May 14.

Pediatric Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address:

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disease, affecting up to 25% of children. Topical corticosteroids (TCS) are currently used as first-line antiinflammatory treatment for AD, due to their overall therapeutic efficacy, and the availability of different potency classes and a wide array of formulations. Therapeutic efficacy of TCS depends upon selecting the appropriate vehicle and potency, and the frequency of application, also taking into account the duration of treatment and patient preferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2020.104878DOI Listing

Prenatal maternal anxiety promotes atopic dermatitis in offspring via placental DNA methylation changes.

Asian Pac J Allergy Immunol 2020 May 17. Epub 2020 May 17.

Department of Pediatrics, Childhood Asthma Atopy Center, Environmental Health Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background: Maternal anxiety during pregnancy has been previously reported to be associated with atopic dermatitis (AD) in offspring. The potential mechanism is not yet proven but epigenetic change may be suggested.

Objective: We examined whether maternal anxiety during pregnancy may alter placental DNA methylation, then develop AD in the offspring. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12932/AP-221119-0699DOI Listing